Gulf Onshore Inc (OTCBB: GFON - News) has changed its name to Cannabis Science, Inc., reflecting its new business mission, and has requested a new stock trading symbol, which will be will be assigned by NASDAQ OMX in the near future. Cannabis Science Inc. has also launched its new website Introducing... reflecting its new name.
The Company's first pharmaceutical cannabis product for DHHS- and FDA-qualified testing will be a whole-cannabis extract in the form of a lozenge. The Company has applied for its DEA handling license and is interviewing researchers to complete and sponsor its IND (Investigational New Drug) test protocols.
The lozenge is a part of the assets and know-how developed by Steven W. Kubby and Dr. Robert J. Melamede and acquired by the Company from Cannex Therapeutics of California.
Initial findings from informal human trials using the whole-cannabis extract demonstrate the lozenge has the capacity to enhance rapid onset through oromucosal absorption. Last year, an early version of the lozenge was tested at Vancouver Island Compassion Society (VICS) (The Vancouver Island Compassion Society Homepage), a non-profit medical cannabis organization located in Victoria, B.C, which is at the forefront of this patient-centered approach to cannabis research.
Cannabis Science, Inc. President & CEO Steven W. Kubby, himself a cancer patient, stated, "As our proof of concept, the study saw seven VICS staff members initially receive 15 lozenges each for a 48 hour period during which they did not use or ingest any other cannabis products. Participants then gave detailed feedback on their experiences by answering a ten-item questionnaire in detail. The study conducted by VICS found that cannabis-based medicine would fill the gap in the market that exists between the fast-acting but short-effect methods of ingestion like smoking, and the long-lasting but slow acting methods like oils and edibles. As well, the VICS Study showed that this type of product would be useful for people suffering from chronic pain or other conditions that appear to benefit from orally-ingested cannabinoid medicines, as well as for those who will not or cannot smoke or vaporize cannabis or who wish to use cannabis-based medicines in an easy and discrete manner. Six of the participants (87.5%) reported feelings of relaxation and/or pain relief. One subject reported "pain relief in my knees with no lethargy or cloudy head," while another "felt really relaxed" and noticed "relief to my muscle aches within 15-20 minutes." The lozenge as a method of delivery is simple and elegant, and the time of onset and length of effect suggests at least modest oromucosal absorption. Naive or elderly patients would respond well to the familiar packaging of a lozenge and to the slower method of delivery and onset of effect compared to smoking or vaporization. It is very important to note that we are not re-inventing the wheel, as another company already has an alcohol-based whole-cannabis extract in FDA Phase 3 human trials in the US so there is ample precedent for such a product. However, we believe patients will be more receptive to our products, which contains no alcohol."
Dr. Robert Melamede, Chief Science Officer for Cannabis Science, Inc., added, "We have determined that the lozenge should be the first modality we use to bring to pharmaceutical cannabis products to market because it brings relatively fast relief to patients in a way that allows them to control their own dosage and does not involve inhalation. It also has the ability to rapidly deliver a wide variety of cannabis pharmaceutical formulations for a broad range of medical needs. The advanced stages of development that Cannex Therapeutics of California has achieved on its lozenge, and the positive informal human testing results it has attained, can speed our process and serve as a guide for formal human testing stages, which all FDA approved drugs must secure before they are released to market in the US."
The Company looks forward to formal human testing to bring various products to market targeting Cancer, Pain relief, Asthma, and Sleep disorders.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. Please visit Introducing... for more information.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact:
Cannabis Science, Inc.
Steven W. Kubby, 888-889-0888
President & CEO
info@cannabisscience.com
Introducing...
News Hawk- Ganjarden 420 MAGAZINE ® - Medical Marijuana Publication & Social Networking
Source: Yahoo!
Contact: Yahoo!
Copyright: 2009 Yahoo! Inc.
Website: Gulf Onshore Announces Name Change to Cannabis Science, Inc. and Selection of Its First Pharmaceutical Cannabis Product for FDA Testing
The Company's first pharmaceutical cannabis product for DHHS- and FDA-qualified testing will be a whole-cannabis extract in the form of a lozenge. The Company has applied for its DEA handling license and is interviewing researchers to complete and sponsor its IND (Investigational New Drug) test protocols.
The lozenge is a part of the assets and know-how developed by Steven W. Kubby and Dr. Robert J. Melamede and acquired by the Company from Cannex Therapeutics of California.
Initial findings from informal human trials using the whole-cannabis extract demonstrate the lozenge has the capacity to enhance rapid onset through oromucosal absorption. Last year, an early version of the lozenge was tested at Vancouver Island Compassion Society (VICS) (The Vancouver Island Compassion Society Homepage), a non-profit medical cannabis organization located in Victoria, B.C, which is at the forefront of this patient-centered approach to cannabis research.
Cannabis Science, Inc. President & CEO Steven W. Kubby, himself a cancer patient, stated, "As our proof of concept, the study saw seven VICS staff members initially receive 15 lozenges each for a 48 hour period during which they did not use or ingest any other cannabis products. Participants then gave detailed feedback on their experiences by answering a ten-item questionnaire in detail. The study conducted by VICS found that cannabis-based medicine would fill the gap in the market that exists between the fast-acting but short-effect methods of ingestion like smoking, and the long-lasting but slow acting methods like oils and edibles. As well, the VICS Study showed that this type of product would be useful for people suffering from chronic pain or other conditions that appear to benefit from orally-ingested cannabinoid medicines, as well as for those who will not or cannot smoke or vaporize cannabis or who wish to use cannabis-based medicines in an easy and discrete manner. Six of the participants (87.5%) reported feelings of relaxation and/or pain relief. One subject reported "pain relief in my knees with no lethargy or cloudy head," while another "felt really relaxed" and noticed "relief to my muscle aches within 15-20 minutes." The lozenge as a method of delivery is simple and elegant, and the time of onset and length of effect suggests at least modest oromucosal absorption. Naive or elderly patients would respond well to the familiar packaging of a lozenge and to the slower method of delivery and onset of effect compared to smoking or vaporization. It is very important to note that we are not re-inventing the wheel, as another company already has an alcohol-based whole-cannabis extract in FDA Phase 3 human trials in the US so there is ample precedent for such a product. However, we believe patients will be more receptive to our products, which contains no alcohol."
Dr. Robert Melamede, Chief Science Officer for Cannabis Science, Inc., added, "We have determined that the lozenge should be the first modality we use to bring to pharmaceutical cannabis products to market because it brings relatively fast relief to patients in a way that allows them to control their own dosage and does not involve inhalation. It also has the ability to rapidly deliver a wide variety of cannabis pharmaceutical formulations for a broad range of medical needs. The advanced stages of development that Cannex Therapeutics of California has achieved on its lozenge, and the positive informal human testing results it has attained, can speed our process and serve as a guide for formal human testing stages, which all FDA approved drugs must secure before they are released to market in the US."
The Company looks forward to formal human testing to bring various products to market targeting Cancer, Pain relief, Asthma, and Sleep disorders.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. Please visit Introducing... for more information.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact:
Cannabis Science, Inc.
Steven W. Kubby, 888-889-0888
President & CEO
info@cannabisscience.com
Introducing...
News Hawk- Ganjarden 420 MAGAZINE ® - Medical Marijuana Publication & Social Networking
Source: Yahoo!
Contact: Yahoo!
Copyright: 2009 Yahoo! Inc.
Website: Gulf Onshore Announces Name Change to Cannabis Science, Inc. and Selection of Its First Pharmaceutical Cannabis Product for FDA Testing
